A tiny fungal molecule being studied to fight cryptococcal infections
Official title: An extracellular vesicle component as a candidate to control cryptococcosis.
Funded at Fundacao Oswaldo Cruz · NIH-11258477 · Data updated 2026-11-12
Researchers are testing whether a small peptide from fungal vesicles (IPI) can help control cryptococcal infections in people with weakened immune systems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fundacao Oswaldo Cruz NIH-funded |
| Lab location | 1 site (Rio de Janeiro, BRAZIL) |
| Project start | March 21, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2026 |
| Award (this year) | $134,240 |
| NIH project number | 5R01AI183314-03 |
| Project ID | NIH-11258477 on NIH RePORTER |
Who could benefit from this research
✓Could help
People at high risk for cryptococcal disease—for example, those with advanced HIV, transplant recipients, or others with weakened immunity—are the population that might benefit from eventual therapies stemming from this work.
✕Less likely to help
Healthy people without risk factors for cryptococcal infection are unlikely to benefit directly from this preclinical research, and it is not an immediate treatment for advanced meningitis right now.
What this research studies
Researchers found a tiny peptide called IPI inside fungal extracellular vesicles that stopped Cryptococcus infection in an insect model. They will study how IPI affects the fungus and the host by doing lab experiments and animal-model work focused on the enzyme DPP4, which influences fungal virulence and host metabolism. The team will use molecular and cellular tests to map how IPI changes fungal behavior and host immune responses. These experiments aim to show whether IPI or related approaches could be developed into new antifungal strategies.
Why it matters
Potential benefit: If successful, this work could point to a new way to prevent or treat cryptococcosis, especially for people with weakened immune systems.
How similar studies have gone: Early laboratory work showed IPI controlled cryptococcal infection in an invertebrate model, but it has not yet been tested in mammals or humans.
Where this research is happening
-
Fundacao Oswaldo Cruz
Rio de Janeiro, Brazil Active
Researchers
- Principal investigator: Rodrigues, Marcio Lourenco — Fundacao Oswaldo Cruz
- Study coordinator: Rodrigues, Marcio Lourenco
Related research
Other NIH-funded projects on the same topics.
-
FIOCRUZ HIV/AIDS Clinical Trials Unit: advancing HIV prevention and treatment in Brazil
A Brazilian clinical trials unit led by Dr. Beatriz Grinsztejn is testing and speeding up new HIV prevention and treatment strategies to help people living with HIV/AIDS and those at risk.
-
FIOCRUZ HIV prevention and treatment center in Rio de Janeiro
This center runs clinical trials of new HIV prevention and treatment approaches for people living with or at risk for HIV in Brazil.
-
How conditional cash payments affect young people's mental health in Brazil
This project looks at whether Brazil's Bolsa Família cash payments are linked to fewer serious mental-health hospitalizations and suicides among children, teens, and young adults.
-
Investigating a component from fungal vesicles to control cryptococcosis.
This study is looking at how a special molecule called IPI might help fight cryptococcosis, a serious fungal infection that mainly affects people with weakened immune systems, to find better ways to treat this condition and improve patient care.
-
Exploring how social factors and cash transfers affect young people's mental health in Brazil
This study looks at how things like poverty and violence affect the mental health of young people in Brazil and explores whether programs that provide cash support can help improve their well-being by making it easier for them to access education and healthcare while also encouraging healthier choices.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.